Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902098 | 1.00 | FOLH1 (0.46) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| SCHEMBL4458797 | 0.84 | FOLH1 (0.58) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| SCHEMBL7902186 | 0.84 | FOLH1 (0.58) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| Hydrochloric Acid SCHEMBL7903946 | 0.83 | FOLH1 (0.57) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| SCHEMBL4460828 | 0.80 | FOLH1 (0.48) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL7902175 | 0.80 | FOLH1 (0.48) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL7900436 | 0.76 | KMT2A (0.69) | FOLH1LMNANAALAD2KMT2A | |
| SCHEMBL8723896 | 0.76 | KMT2A (0.69) | FOLH1LMNANAALAD2KMT2A | |
| SCHEMBL9014687 | 0.76 | CA2 (0.56) | FOLH1LMNAKMT2A | |
| SCHEMBL1064767 | 0.76 | CA2 (0.56) | FOLH1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |